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Introduction 
Arterial hypertension represents one of the most common diseases in developed countries 
affecting 30–45% of the adult European population (Mancia et al., 2013). Primary 
aldosteronism is the most frequent cause of endocrine hypertension with a prevalence of 7–
10% among unselected hypertensive patients (Rossi et al., 2006, Hannemann et al., 2012). 
Primary aldosteronism is characterized by inadequately high aldosterone values, suppressed 
plasma renin concentrations, hypertension and hypokalemia. It develops from autonomous 
hypersecretion of the mineralocorticoid aldosterone, independent from angiotensin II 
stimulation and non-suppressible by sodium load.  Aldosterone is rapidly synthesized in the 
zona glomerulosa cells upon stimulation of the renin-angiotensin-aldosterone system (RAAS). 
Several enzymes are involved in this steroidogenic process. Early studies identified 
steroidogenic acute regulatory protein (StAR) to initiate the adrenal pathway of 
steroidogenesis with the translocation of cholesterol from the outer to the inner mitochondrial 
membrane (Black et al., 1994, Clark et al., 1994, Spät and Hunyady 2004). StAR (STARD1) 
expression is stimulated by ACTH and Ca2+ mediated stimuli such as angiotensin II and 
potassium (Spät and Hunyady 2004). The cholesterol side-chain cleavage enzyme 
(CYP11A1) catalyzes the conversion of cholesterol to pregnenolone at the matrix side of the 
inner mitochondrial membrane (Hum and Miller 1993). Pregnenolone exits the mitochondria 
and 3-b-hydroxysteroid dehydrogenase of the microsomal compartment transforms it to 
progesterone. Subsequently, progesterone undergoes 21-hydroxylation to form 11-
desoxycorticosterone (Otis and Gallo-Payet 2007). The aldosterone synthase (CYP11B2) is 
involved in the last steps of aldosterone biosynthesis catalyzing the 11-β-hydroxylation and 
18-oxidation of 11-desoxycorticosterone to corticosterone and furthermore the 18-
hydroxylation of corticosterone and 18-oxidation of 18-OH-corticosterone, finally resulting in 
the production of aldosterone (Curnow et al., 1991). CYP11B2 is transcriptionally regulated 
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by the nuclear transcription factors NGF1-B (NR4A1) and NURR1 (NR4A2), whose 
expression is in turn stimulated by angiotensin II (Bassett et al., 2004). 
There are two major causes of primary aldosteronism: aldosterone-producing adrenal 
adenomas and bilateral adrenal hyperplasia (Mulatero et al., 2004, Rossi et al., 2006). Despite 
its high prevalence, so far, the genetic background of primary aldosteronism due to bilateral 
hyperplasia has been elucidated only in a small subgroup of cases: Familial 
hyperaldosteronism type I (FH-1, glucocorticoid remediable hyperaldosteronism) is an 
autosomal dominant disorder, caused by unequal crossing-over of the CYP11B1 and 
CYP11B2 and the formation of a hybrid gene (Sutherland et al., 1966, Lifton et al., 1992). 
FH-1 patients present an ACTH-dependent production of aldosterone, independent from 
angiotensin II regulation. Familial hyperaldosteronism type II (FH-2) also appears to be 
inherited as an autosomal dominant trait. Linkage studies performed in two Australian, one 
South American and two Italian families demonstrated association with a locus on 
chromosome 7p22 (Gordon et al., 1991, So et al., 2005), but the linkage area could not be 
correlated to any causative mutation. Familial hyperaldosteronism type III (FH-3), 
characterized by early-onset hypertension, profound hypokalemia and significant 
overproduction of 18-oxocortisol and 18-hydroxycortisol (Geller et al., 2008), however, has 
been recently associated to gain-of-function mutation in the KCNJ5 gene, encoding an 
inwardly rectifying potassium channel (Choi et al., 2011). KCNJ5 mutations lead to a loss in 
channel selectivity and by that to continuous membrane depolarization and increased 
intracellular Ca2+ concentrations resulting in aldosterone excess. These mutations are more 
prevalent in younger patients and in women and correlate with higher plasma aldosterone 
levels (Boulkroun et al., 2012). Additionally, somatic mutations in ATP1A1 and ATP2A3, two 
members of the P-type ATPase gene family, were identified by exome sequencing in 
aldosterone producing adrenal adenomas (Beuschlein et al., 2013, Fernandes-Rosa et al., 
2014). Finally, germline mutations in the Ca2+-channel genes CACNA1D (Scholl et al., 2013) 
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and CACNA1H (Scholl et al., 2015) were recently identified as a rare cause of early onset 
primary aldosteronism. Taken together, genetics of the vast majority of cases of bilateral 
adrenal hyperplasia remain enigmatic. 
Mice provide a valuable model for the investigation of mechanisms involved in blood 
pressure regulation and specifically for the study of the RAAS. Several animal models with 
targeted genetic alterations such as Task1 and Task3 knockout mice (Davies et al., 2008, 
Heitzmann et al., 2008) and a circadian clock-deficient cry-null mouse model showing an 
upregulation of the adrenal Hsd3b6 (Doi et al., 2010) have been presented to date.  
A method for development of new mouse models with a specific phenotype is random 
mutagenesis of the mouse genome using the mutagenic substance N-ethyl-N-nitrosourea 
(ENU) (Clark et al., 2004). ENU is an alkylating agent inducing ethylation of nucleic acids, 
which finally results in point mutations. This enables the production of many F1 founder 
animals from a single treated male, reducing the number of animals receiving ENU-handling. 
Approximately 1 in 1000 F1 animals is heterozygous for a functionally relevant mutation of 
interest, according to the specific-locus test (Russell et al., 1979). Specific screening tools 
should then be applied to distinguish a sometimes-mild effect (Rossant and Scherer 2003). In 
such a phenotype-driven genetic approach the genomic association is finally achieved either 
by linkage analysis using single nucleotide polymorphisms (SNPs) or exome sequencing. 
Inbred mouse strains, which are progenitors of chromosome substitution strains (CSS) and 
recombinant inbred strains (RIS), can be utilized for mapping the position of a gene effect. 
Linkage analysis upon crossbreeding of mutant animals from one strain to wild-types from 
another can associate the phenotype with a small locus on the genome, hosting the causative 
gene for the investigated trait. However, C57BL/6J and C3H/HeJ inbred strains, which 
constitute the genetic background of the available CSS and one of the RIS panels, present 
variations in several physiological and behavioral traits (Singer et al., 2004) and such 
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differences of the respective investigated phenotype need to be defined to prevent from 
misleading genetic associations.  
Genome-wide association studies (GWAS) are important tools for the identification of 
common genetic susceptibility loci in human heredity and disease. This method uses 
genotyping arrays of a dense set of common single-nucleotide polymorphisms to generate 
genotypes in large populations of cases and controls (Frazer et al., 2007). GWAS improved 
our knowledge on hereditary characteristics leading to predisposition to diseases influenced 
from both genetic and environmental factors (Hirschhorn and Daly, 2005). In fact, in two 
recent GWAS, both systolic and diastolic blood pressure could be associated with 16 and 107 
independent loci, respectively, containing genes that regulate blood pressure (Ehret et al., 
2011, Warren et al., 2017). As in investigations utilizing inbred mouse strains, in population-
based studies was demonstrated that the aldosterone to renin ratio (ARR) is an inherited 
characteristic and can be correlated with the risk of blood pressure progression and incident 
hypertension (Newton-Cheh et al., 2007). 
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Objectives 
First aim of the work present herein was to examine the physiological regulation of 
parameters of the adrenal aldosterone secretion by defining immediate transcriptional changes 
that take place in the adrenal gland upon specific stimulation and suppression experiments 
modulating aldosterone secretion in vivo.  As the basis for upcoming exploration of potential 
genetic mechanisms involved in the modulation of aldosterone secretion it was further 
necessary to determine the differences in aldosterone values and the molecular differences in 
C3HeB/FeJ and C57BL/6J inbred mouse strains. Subsequently, in an attempt to define novel 
genetic loci involved in the pathophysiology of primary aldosteronism, an ENU-mutagenesis 
screen for the parameter aldosterone had to be established, followed by the phenotypic and 
genetic characterization of identified mouse lines. A parallel approach for the detailed 
molecular and functional characterization of genes involved in the regulation of the RAAS 
was to examine candidate genes identified by GWAS in a population-based study. 
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Studies carried out and main findings 
1. Determinants of baseline aldosterone secretion in mice 
Spyroglou A, Sabrautzki S, Rathkolb B, Bozoglu T, Hrabé de Angelis M, Reincke M, 
Bidlingmaier M, Beuschlein F. Gender-, strain-, and inheritance-dependent variation in 
aldosterone secretion in mice. J Endocrinol. 2012 Dec;215(3):375-81.  
 
Aim of this study was to determine the differences in regulation of aldosterone production in 
C3HeB/FeJ and C57BL/6J inbred mouse strains as the basis for future exploration of potential 
genetic mechanisms involved in the modulation of aldosterone secretion. Therefore, 
aldosterone and renin levels as well as the adrenal steroidogenic profile were defined in male 
and female mice of two inbred strains, C3HeB/FeJ and C57BL/6J, and their offspring of the 
F1 and F2 generation (for nomenclature refer to Table 1).  
Measurement of baseline aldosterone levels in male and female mice of the strain C3HeB/FeJ 
(CCCC) revealed baseline aldosterone values of 134±11 and 78±5 pg/ml respectively, which 
resulted in a statistically significant difference between the genders (P<0.001, Table 2). 
Similarly, male C57BL/6J (BBBB) had significantly higher aldosterone values than their 
female littermates (P<0.01, Table 2). Additionally, BBBB animals presented significantly 
higher values than CCCCs for both genders. Upon mating of male BBBB to female CCCC or 
male CCCC to female BBBB mice, all F1 offspring were tested for their aldosterone values. 
Also in these F1 mice, significant gender differences in aldosterone values were documented 
(BBCC males vs. females P<0.05; CCBB males vs. females P<0.05). Furthermore, animals 
carrying C3HeB/FeJ genetic background presented a tendency toward lower aldosterone 
values. Further mating of those male and female F1 offspring to inbred BBBBs of both 
genders gave rise to F2 animals with a mixed genetic background. Depending on the extent of 
C57BL/6J genetic background on the paternal side, plasma aldosterone values showed a 
gradual reduction, with male animals having in all cases higher aldosterone than their female 
littermates (Table 2). 
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Table 1: Nomenclature for C3HeB/FeJ 
and C57BL/6J mice and their F1 and F2 
offspring. Reproduced from Spyroglou et 
al., 2012.  
 
 
Table 2: Aldosterone values (pg/ml) of 
male and female C3HeB/FeJ, C57BL/6J 
mice and their F1 and F2 offspring. 
Adapted from Spyroglou et al., 2012. 
Subsequently, focus was put on the F2 animals and a more detailed phenotypical 
characterization concerning their RAAS was performed. No differences in renin values could 
be observed among the groups of both genders (males P=0.27, females P=0.96). Likewise, 
calculation of the aldosterone to renin ratio (ARR) showed no differences within the groups 
for both male (P=0.99) and female (P=0.27) animals (Table 3). The potassium values did not 
indicate any specific tendency within the examined groups (males, P=0.37; females, P=0.10) 
and overall remained within the normal range. Kidney parameters creatinine and urea were 
also defined in the F2 offspring of both genders and in all instances remained within the 
normal range without evident differences among the examined groups (creatinine: males, 
P=0.55 and females, P=0.36; urea: males, P=0.18 and females, P=0.86, Table 3). 
On the molecular level, quantification of the adrenal expression levels of steroidogenic 
enzymes involved in aldosterone synthesis displayed the same trend as the aldosterone values 
themselves, with animals hosting C57BL/6J background in their paternal origin having also 
the highest expression levels for StAR, cyp11a1, and cyp11b2 enzymes. In details, StAR 
showed the highest expression in BBBC male and female animals and the lowest in CBBB 
animals (males P<0.05; females P<0.01). Similar was the tendency for cyp11a1 expression 
which was highest in BBBCs, with a gradual reduction in BBCBs and BCBBs and the lowest 
levels in CBBBs (males P<0.001; females P<0.001). The same observation was obtained for 
the cyp11b2 (P<0.05 for both genders, Table 3). 
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Taken together, these data reveal gender- and strain-dependent differences in the baseline 
aldosterone levels in age-matched mice and demonstrate that the genetic background of the 
animals plays a significant role modulating their plasma aldosterone levels without distinct 
impact on other parameters of the RAAS. 
Males Aldo Renin ARR K+ Crea Urea StAR cyp11a1 cyp11b2 
 (pg/ml) (ng/ml/hr) (pg/ml/ ng/ml/hr) (mmol/l) (mg/ml) (mg/ml) (%) (%) (%) 
BBBC 225±19 93.7±22 3.8±0.9 5.1±0.13 0.35±0.01 61,4±1 100±11 100±10 100±14 
BBCB 213±12 73.3±9 4.0±1.0 4.7±0.11 0.35±0.01 58.5±2 81.8±3 81.4±5 79.8±5 
BCBB 180±12 60.7±10 3.8±0.9 4.9±0.11 0.36±0.01 57.3±4 84.7±8 67.6±6 65.3±8 
CBBB 175±14 42.5±8 3.8±0.6 4.8±0.13 0.34±0.01 56.3±2 61.9±6 52.1±2 65.9±8 
P value <0.05 0.2719 0.9958 0.3737 0.5562 0.1881 <0.05 <0.001 <0.05 
Females Aldo Renin ARR K+ Crea Urea StAR cyp11a1 cyp11b2 
 (pg/ml) (ng/ml/hr) (pg/ml/ ng/ml/hr) (mmol/l) (mg/ml) (mg/ml) (%) (%) (%) 
BBBC 172±12 51.5±7 3.8±0.4 4.6±0.16 0.33±0.01 59.5±2 100±7 100±6 100±13 
BBCB 169±12 53±13 3.5±0.6 4.3±0.11 0.35±0.01 50.2±3 78.4±4 88±5 62.1±6 
BCBB 140±15 52.2±10 3.2±0.9 4.6±0.12 0.35±0.01 58.2±2 83.3±6 86.3±7 58.4±7 
CBBB 115±15 53.1±4 2.6±0.2 4.2±0.07 0.34±0.01 49.6±3 73.7±3 58.4±3 56.9±5 
P value <0.05 0.9603 0.2660 0.1054 0.3592 0.8599 <0.01 <0.001 <0.05 
 
Table 3: Aldosterone (pg/ml), renin (ng/ml per h), ARR (pg/ml per ng per ml per h), 
potassium (mmol/l), creatinine (mg/ml), urea (mg/ml), and levels of expression of the 
enzymes StAR, cyp11a1 and cyp11b2 for the groups BBBC, BBCB, BCBB, and CBBB of 
both genders. Adapted from Spyroglou et al., 2012. 
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2. In vivo regulation of aldosterone secretion 
Spyroglou A, Manolopoulou J, Wagner S, Bidlingmaier M, Reincke M, Beuschlein F. Short 
term regulation of aldosterone secretion after stimulation and suppression experiments in 
mice. J Mol Endocrinol. 2009 May;42(5):407-13.  
 
In this study, the murine adrenal steroidogenic response and aldosterone secretion was 
investigated upon specific functional tests. More specifically, one group of 35 mice received 
an i.p. angiotensin II injection, the second an i.p. sodium load and the third a sham injection. 
In each one of three groups 5 animals were euthanized at baseline and at following time 
points (10, 20, 30, 40, 60 and 120 min) upon injection.  Their plasma aldosterone levels and 
the adrenal expression of enzymes involved in steroidogenesis were subsequently defined.  
In the control group, aldosterone secretion in animals 10 min after sham injection was 
significantly higher than under baseline conditions (P<0.005) but already at 30 min and 
thereafter dropped back to levels comparable with baseline values (Figure 1). qPCR analysis 
revealed an increase of StAR expression over the baseline values only 20 min after the sham 
injection (P<0.05), sustained until 60 min later (P<0.05). Similarly, Cyp11a1 expression 
started increasing 20 min after the sham injection (P<0.001) and did not normalize within the 
observation period (P<0.05). By contrast, Cyp11b2 expression showed an increase already 10 
min after the injection (P<0.05) and rapidly normalized in the 20-min group (P=0.93) and 
thereafter (Figure 2A). NGF1-B expression was significantly upregulated already after 10 min 
(P<0.001) whereas Nurr1 expression showed a transient decrease up to 20 min (P<0.05) and 
subsequently a slight increase (P<0.05, Figure 3A). 
Ten minutes after the angiotensin II injection, the aldosterone concentration was significantly 
elevated in comparison to baseline (P<0.001). The subsequent measurements showed a 
stepwise reduction while aldosterone secretion remained significantly higher in comparison 
with the baseline values (P<0.01, Figure 1). A parallel increase in StAR and Cyp11a1 
expression could be observed already 10 min upon injection (StAR P<0.05, Cyp11a1 P<0.01) 
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with a peak of StAR mRNA levels at 20 min (P<0.05) and sustained elevation of both 
enzymes until 120 min later (StAR P<0.05, Cyp11a1 P<0.01). Furthermore, angiotensin II 
injection resulted in a significant increase in Cyp11b2 expression after 10 min (P<0.005) 
which was continued up to 60 min later (P<0.01, Figure 2B). Upregulation of Cyp11b2 
expression was significantly higher in the angiotensin II group in comparison with the sham 
injection group (P<0.01 for time points 10–60 min). A pronounced increase in the expression 
of both NGF1-B and Nurr1 could be documented already 20 min after injection (Nurr1 
P<0.01, NGF1-B P<0.001) which lasted up to 60 min (Nurr1 P<0.005, NGF1-B P<0.001, 
Figure 3B). 
 
Figure 1: Aldosterone values in control 
animals after sham injection, after 
angiotensin II stimulation and upon NaCl 
suppression. Stars denote significant 
changes over baseline values (i.e., 0 min). 
Reproduced from Spyroglou et al., 2009. 
After i.p. injection of 1 ml NaCl 0.9%, aldosterone secretion showed a short-term increase 
(P<0.005) comparable with that seen after sham injection. This initial peak was followed by a 
slow decrease with the lowest aldosterone levels 60 min after the injection, significantly lower 
in comparison with baseline values (P<0.005, Figure 1). Both StAR and Cyp11a1 expressions 
were reduced upon sodium load between 20 min (StAR P<0.001, Cyp11a1 P<0.001) and 60 
min (StAR P<0.05, Cyp11a1 P<0.05). Furthermore, sodium load had significant effects on 
Cyp11b2 expression levels that remained suppressed between 20 min (P<0.05) and 60 min 
(P<0.01, Figure 2C). Thirty min after the sodium load, Nurr1 mRNA displayed a transient 
increase (P<0.05) and later a progressive decrease with a significant drop under baseline 
parameters after 120 min (P<0.005). NGF1-B expression, however, displayed a constant and 
significant increase during the first hour (10 min: P<0.05, 40 min: P=0.01, Figure 3C) as after 
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sham and angiotensin II injection. While increases in NGF1-B mRNA levels were similar 
between the treatment groups, Nurr1 expression levels were induced only upon angiotensin II 
administration.  
 
 
Figure 2: (A) Increase or decrease of the 
mRNA expression levels of StAR, 
Cyp11a1, and Cyp11b2 genes in the 
control group upon sham injection, (B) 
after angiotensin II stimulation, and (C) 
after NaCl challenge. Stars denote 
significant changes for each gene over 
baseline expression levels which are set as 
100% for each gene. Reproduced from 
Spyroglou et al., 2009. 
 
Figure 3: (A) Increase or decrease of the 
mRNA expression levels of Nurr1 and 
NGF1-B in the control group upon sham 
injection, (B) after angiotensin II 
stimulation, and (C) after NaCl challenge. 
Stars denote significant changes for each 
gene over baseline expression levels which 
are set as 100% for each gene. Reproduced 
from Spyroglou et al., 2009. 
Taken together, these data demonstrate that regulation of aldosterone secretion upon specific 
stimulation and suppression paradigms in vivo is achieved by short term transcriptional 
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changes of key steroidogenic enzymes and nuclear transcription factors. From the investigated 
parameters on the mRNA level StAR, Cyp11a1 and NGF1-B appear to respond more to 
unspecific stress-related effects, whereas Cyp11b2 and Nurr1 are preferentially regulated by 
specific stimulation of the RAAS. 
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3. Mutagenesis screen for primary aldosteronism 
Spyroglou A, Wagner S, Gomez-Sanchez C, Rathkolb B, Wolf E, Manolopoulou J, Reincke 
M, Bidlingmaier M, Hrabé de Angelis M, Beuschlein F. Utilization of a mutagenesis screen to 
generate mouse models of hyperaldosteronism. Endocrinology. 2011 Jan;152(1):326-31. 
 
The ENU-mutagenesis screen was utilized for the phenotype hyperaldosteronism and the 
aldosterone values of all 12-weeks-old F1 offspring from ENU-treated males and wild-type 
females were measured. The normal range of aldosterone values was defined as mean + 3 SD 
of a wild-type age and gender matched population. In the initial screen 2864 mice took part: 
1450 male and 1414 female animals. Of this cohort 83 animals initially presented aldosterone 
values above the normal range (18 males and 65 females; Figure 4, left panel). All animals 
that showed once pathological aldosterone levels were retested at the age of 16 weeks and 
upon confirmation measurement, only 11 mice had constantly high aldosterone values (two 
males and nine females; Figure 4 right panel). These were then mated to wild-type animals of 
the opposite gender. Two mice with abnormal aldosterone levels died due to undefined 
reasons, before further breeding could take place and one mouse gave rise solely to unaffected 
offspring, so that finally only eight lines with affected offspring could be generated. Taken 
together, 2.9% of all offspring tested for hyperaldosteronism showed initially high aldosterone 
values. From these 13.2% had sustained hyperaldosteronism (females: 81.8%, males:18.2%). 
In total, 0.38% of all mice screened had confirmed hyperaldosteronism. 
 
Figure 4: Aldosterone values of F1 offspring of ENU-treated mice at 12 weeks (females, 
n=1414; males, n=1450; left panel) and at the age of 16 weeks (females, n=65; males, n=18; 
right panel), respectively. Horizontal bars represent cut-off levels defined as 3 SDs above the 
mean of gender- and age-matched controls. Adapted from Spyroglou et al., 2011.  
16 
 
Affected F2 animals of the eight established lines were then further bred by mating to wild-
type mice of the opposite gender. From the pedigrees obtained we could gain first evidence 
for possible patterns of inheritance of the trait of hyperaldosteronism. In all pedigrees, the 
founder animal originated from a different ENU-treated male parent, so that it is very 
probable that different mutations are the genetic cause of the investigated phenotype in each 
case. Accordingly, different patterns of inheritance between individual pedigrees were 
observed (Figure 5 and Table 4): In line I, male and female animals were both affected in 
approximately 35% of the cases. In line III the pathological phenotype was present in both 
male and female mice in 27% and 22% of animals, respectively, with total male to female 
ratio of 1.5:1. In line V only male animals were affected at a rate of 38%, with total male to 
female ratio 4:3. From line VIII 30% of the males and 28% of the females showed 
hyperaldosteronism. However, in this mouse line the total male to female ratio was 2:1, 
possibly because of excess mortality in female offspring.  
A penetrance of the investigated phenotype above 50% is considered as suitable for an ENU 
screen (Aigner et al., 2008). In our cohort, all but one mouse lines showed a suitable 
penetrance in either one or both genders (Table 4). In mouse line IV, where penetrance is 40 
and 45%, in females and males, respectively, breeding over two generations showed 
preservation of the abnormal phenotype. Further aldosterone measurements in older animals 
(20 weeks old) revealed a trend to higher penetrance with increasing age. In all eight lines, the 
numbers of animals displaying abnormal plasma aldosterone levels (using as cut-off: mean + 
3 SD) were significantly (P<0.001) higher than the expected 0.3% of the C3HeB/FeJ mouse 
population. 
Taken together, in this study we have demonstrated the utility of a phenotype-driven 
mutagenesis screen for the identification of mouse lines with chronic hyperaldosteronism.  
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Figure 5: Pedigrees with hyperaldosteronism generated from the ENU screen. Black symbols 
denote affected animals. Reproduced from Spyroglou et al., 2011. 
 
 
Table 4: Percentages of affected male and female mice and their respective penetrances. 
Phenotypic penetrance (100%) is defined in the case of the appearance of 50% offspring 
exhibiting hyperaldosteronism after mating phenotypic mutants to wild-type mice. The 
observed penetrance in individual mouse lines was calculated by number of affected animals: 
(all animals: 2) and expressed as percent. Adapted from Spyroglou et al., 2011. 
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4. Reverse genetics for primary aldosteronism 
Perez-Rivas LG, Rhayem Y, Sabrautzki S, Hantel C, Rathkolb B, Hrabé de Angelis M, 
Reincke M, Beuschlein F, Spyroglou A. Genetic characterization of a mouse line with 
primary aldosteronism. J Mol Endocrinol. 2017 Feb;58(2):67-78. 
 
One of the previously described ENU-generated mouse lines with hyperaldosteronism was 
genetically characterized. Upon next-generation sequencing (NGS) applied on two different 
affected animals of this mouse line, a list with 31 single-nucleotide variations (SNV) was 
generated; eight of those were common for both investigated animals: SCO-spondin (Sspo), 
deoxyguanosine kinase (Dguok), 5730446D14Rik (Hoxa cluster antisense RNA 2 – 
Hoxaas2), calsyntenin 3 (Clstn3), all four on chromosome 6, integrator complex subunit 10 
(Ints10), on chromosome 8, ataxia telangiectasia mutated (Atm), timeless interacting protein 
(Tipin) and mitogen-activated protein kinase 6 (Mapk6), the latest three on chromosome 9. 
These were subsequently sequenced in a large cohort (n = 126, 63 females, 63 males) of 
phenotypically ‘affected’ and ‘unaffected’ animals of this mouse line. Ints10 was not found 
mutated in the examined cohort of animals and was excluded from further analyses.  
All animals of this cohort were stratified into wild-type and mutant according to their 
genotypes for each of the candidate genes to enable association of each identified candidate 
gene with the phenotype of hyperaldosteronism. Thereby, we aimed at isolating a potential 
effect of one mutation on the investigated phenotype even though the random presence of 
mutant variants of the other candidate genes might have further modulating effects. We 
correlated the genotype with the respective aldosterone, urea and creatinine values as well as 
steroidogenic enzyme expression levels. We observed significantly increased plasma 
aldosterone values in animals with Sspo (P<0.01), Dguok (P<0.01), Hoxaas2 (P<0.01) and 
Clstn3 (P<0.001) mutation (Figure 6). Urea and creatinine levels did not differ significantly 
among wild-type and mutated animals.  
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Figure 6: Aldosterone values in wild-type 
or mutant animals (n = 126) for each of the 
following genes: Sspo, Dguok, Hoxaas2, 
Clstn3, Atm, Tipin and Mapk6. Values are 
expressed as % of the mean aldosterone 
levels of wild-type male or female mice, 
respectively. Reproduced from Perez-
Rivas et al., 2017. 
StAR expression levels were significantly lower in Clstn3-mutants (P<0.05, Figure 7A) and 
Cyp11a1 expression was reduced in Sspo (P<0.05), Dguok (P<0.01), Hoxaas2 (P<0.01), 
Clstn3 (P<0.001) and Atm (P<0.05) mutants (Figure 7B). Hsd3b6 levels were lower in Clstn3 
(P<0.05), Atm (P<0.01), Tipin (P<0.05) and Mapk6 (P<0.05) mutated animals (Figure 7C). 
No differences could be found for Cyp11b1 expression levels for any of the mutations 
investigated (Figure 7D). In Sspo-mutated animals, Cyp11b2 expression was significantly 
higher (P<0.05), whereas Dguok-mutated animals tended to present higher Cyp11b2 levels, 
without reaching statistical significance (P=0.07, Figure 7E). The orphan nuclear factor 
Nurr1, showed higher expression levels in Sspo- (P<0.05) and Hoxaas2- (P<0.05) mutated 
mice (Figure 7F).  
From the results presented in Figure 6, it is apparent that Atm, Tipin and Mapk6 do not 
associate with the phenotype of primary aldosteronism since aldosterone values of wild-types 
were significantly higher than those of animals carrying one, two or all three above mentioned 
SNVs. To further narrow down the list to one causative SNV from the remaining four genes 
(Sspo, Dguok, Hoxaas2 and Clstn3), aldosterone levels of animals excluding mice carrying 
Atm and/or Tipin and/or Mapk6 mutations were compared. Animals carrying Sspo and/or 
Dguok and/or Hoxaas2 and/or Clstn3 SNVs demonstrated significantly higher aldosterone 
values than wild-type only animals and the mutant-to-wild-type ratio of aldosterone levels 
was in all cases higher in this restricted analysis (Table 5). 
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Figure 7: Expression levels of steroidogenic enzymes involved in aldosterone biosynthesis in 
wild-type or mutant animals (n = 33) for each of the following genes: Sspo, Dguok, Hoxaas2, 
Clstn3, Atm, Tipin and Mapk6. Values are relatively expressed to the housekeeping gene 
Gapdh. Reproduced from Perez-Rivas et al., 2017. 
 
cohort Sspo Dguok 
 wt mut fold p wt mut fold p 
All (n=126) 351±120 405±132 1.15 <0.05 354±127 408±120 1.15 <0.05 
Restricted (n=99) 349±107 426±128 1.22 <0.01 354±117 431±114 1.22 <0.01 
cohort Hoxaas2 Clstn3 
 wt mut fold p wt mut fold p 
All (n=126) 350±119 413±132 1.18 <0.01 346±116 428±132 1.23 <0.001 
Restricted (n=99) 346±106 436±126 1.26 <0.001 341±101 459±123 1.34 <0.0001 
 
Table 5: Aldosterone plasma levels (pg/mL, mean ± s.d.) in animals with the respective 
genotype in the whole cohort (all) and excluding animals with mutations in Atm, Tipin and/or 
Makp6 (restricted). Adapted from Perez-Rivas et al., 2017. 
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Aldosterone to Renin Ratio (ARR) 
 mean ± sd 
(% of mean of wt) P 
Sspo 
 
wt (n=24) 100 ± 43 <0.05 
mut (n=17) 142 ± 71 
Dguok 
 
wt (n=27) 100 ± 49 =0.09 
mut (n=14) 130 ± 60 
Hoxaas2 
 
wt (n=27) 100 ± 47 =0.10 
mut (n=14) 130 ± 65 
Clstn3 
 
wt (n=26) 100 ± 46 =0.80 
mut (n=15) 96 ± 55 
 
Table 6: Aldosterone-to-renin ratio of all 
experimental animals. In each line ‘mut’ 
denotes those mice which carry at least the 
respective mutant gene, whereas ‘wt’ 
combine those with the absence of the 
mutant gene. Adapted from Perez-Rivas et 
al., 2017. 
 
Plasma renin activity did not show any significant differences between animals with wild-type 
and mutant genotype for the above four SNVs. Calculation of the aldosterone-to-renin ratios 
(ARR) demonstrated a significant ARR increase only in mice carrying the Sspo SNV (Table 
6). Mice with the Dguok and/or Hoxaas2 SNV also presented a trend toward increased ARRs. 
Histological examination of the adrenal glands of animals carrying all four SNVs (Sspo, 
Dguok, Hoxaas2 and Clstn3) did not reveal any structural abnormalities such as 
adrenocortical adenomas. Moreover, there was no sign of adrenocortical hyperplasia as the 
cell count of the outer, middle and inner cortical area of these animals did not differ 
significantly from the wild-types (P=0.45, P=0.80 and P=0.29, respectively). However, upon 
immunohistochemical staining with murine CYP11B2 antibody, significantly more positively 
stained cells were present in the adrenal cortex of mutant animals in comparison to the wild-
types (P<0.001, Figure 8A, B and C). Furthermore, CYP11B2 staining of the middle 
(P<0.001) and inner (P<0.001) cortical area was significantly more pronounced in mutant 
mice, suggesting alternated zonation pattern in animals with the four SNVs (Figure 8D–F).  
Taken together, the characterization of this mouse line led to the identification of seven 
candidate genes for the investigated phenotype of primary aldosteronism. From the identified 
candidates Atm, Tipin and Mapk6 appear to be irrelevant to the investigated phenotype, 
whereas no definite conclusion can be reached in the case of the role of Sspo, Dguok, 
Hoxaas2 and Clstn3 in primary aldosteronism. Thus, further efforts will be necessary to rule 
in or out the role of these four genes in the pathogenesis of primary aldosteronism. 
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Figure 8: Histological examination of the adrenal glands of wild-type animals and mutants 
for all four following genes: Sspo, Dguok, Hoxaas2 and Clstn3. Cell count of CYP11B2 
positively stained cells per standardized area in the adrenal cortex of wild-type and mutant 
animals to the total cell count per area (A). Representative immunohistochemical staining of 
the adrenal cortex of wild-type (B) and mutant (C) mice. Ratios of CYP11B2 positively 
stained cells to the total cell count in the outer (D), middle (E) and inner (F) area of the 
adrenal cortex of wild-type and mutant mice (*** for P<0.001). Reproduced from Perez-
Rivas et al., 2017. 
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5. Genome-wide association studies for primary aldosteronism 
Spyroglou A, Bozoglu T, Rawal R, De Leonardis F, Sterner C, Boulkroun S, Benecke AG, 
Monti L, Zennaro MC, Petersen AK, Döring A, Rossi A, Bidlingmaier M, Warth R, Gieger C, 
Reincke M, Beuschlein F. Diastrophic dysplasia sulfate transporter (SLC26A2) is expressed 
in the adrenal cortex and regulates aldosterone secretion. Hypertension. 2014 
May;63(5):1102-9. 
 
A parallel approach for the detailed molecular and functional characterization of genes 
involved in the regulation of the RAAS was to examine candidate genes identified by 
genome-wide association study (GWAS) in a population-based study. The GWAS was 
performed on 1786 subjects of the Cooperative Health Research in the Region of Augsburg 
F4 cohort. A strong linkage of the ARR to chromosome 5 reaching genome-wide significance 
(P=6.78Χ10–11; Figure 9A) could be demonstrated. The identified locus harbored four genes 
SLC26A2, HMGXB3 (HMG box domain containing 3), TIGD6 (tigger transposable element 
derived 6), and CSF1R (colony-stimulating factor 1 receptor) (Figure 9B). There was no 
evidence that the CSF1-CSF1R system has a functional effect in aldosterone secretion. On the 
contrary, SLC26A2 has a known function as transporter and showed an interesting expression 
pattern upon initial expression studies. Thus, SLC26A2 was chosen for further investigation. 
 
 
 
Figure 9: Genome-wide association study 
for aldosterone to renin ratio. (A) GWAS 
of 1786 subjects from the Cooperative 
Health Research in the Region of 
Augsburg F4 population using 1000 K 
Affymetrix chip, and the ARR are depicted 
as a Manhattan plot, demonstrating a 
genome-wide significant locus 
(P=6.78Χ10–11) within chromosome 5. (B) 
Zooming into the specific locus indicates 
position of genes within this region 
including SLC26A2, HMGXB3, TIGD6, 
and CSF1R. Adapted from Spyroglou et 
al., 2014. 
 
After real-time PCR analysis in wild-type mice, highest levels of slc26a2 were identified in 
murine adrenal glands in comparison with kidney (P<0.001), lung (P<0.001), heart (P<0.001), 
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liver (P<0.001), and spleen (P<0.001) among other organs (Figure 10A). 
Immunohistochemically, adrenocortical expression of SLC26A2 was clearly documented in 
normal human adrenal glands, however, less intensive in aldosterone producing adrenal 
adenomas (APAs). Likewise, expression of SLC26A2 was readily detectable in the human 
adrenocortical cell line NCI-H295R (Figure 12A). Furthermore, APAs displayed significantly 
lower SLC26A2 levels than normal adrenal tissues (P<0.0001; Figure 10B), independently of 
sex (Figure 10C) or any underlying somatic mutation in KCNJ5 or ATPase (ATP1A1 and 
ATP2B3) in these adenomas (Figure 10D). 
 
 
 
 
 
 
Figure 10: Expression of SLC26A2 in 
murine tissues and human aldosterone 
producing adenomas. (A) Investigation of 
tissue distribution in wild-type mice 
demonstrates slc26a2 expression to be 
highest in adrenal glands in comparison 
with a variety of other tissues. (B–D) 
SLC26A2 expression is significantly lower 
in APAs (n=91) in comparison with 
control adrenal glands (normal adrenal, 
n=11; B). Within the groups of APAs, 
expression was independent of sex (C) or 
underlying somatic mutation in KCNJ5 
(KCNJ5+), ATP1A1, and ATP2B3 
(ATPase+; D). Adapted from Spyroglou et 
al., 2014. 
We next investigated slc26a2 expression in wild-type mice treated with angiotensin II and 
potassium, known stimulators of the aldosterone secretion. Short-term stimulation with 
angiotensin II caused a significant downregulation of adrenal slc26a2 expression at 120 
minutes (P<0.05; Figure 11A). Similarly, after potassium supplementation in the drinking 
water for 1 week, adrenal slc26a2 expression was significantly downregulated at day 1 
(P<0.05) and day 4 (P<0.05) while this effect was less pronounced at the end of the 
experiment (Figure 11B). Thus, these findings demonstrated relevant adrenal slc26a2 
expression changes upon experiments affecting the RAAS system, suggesting a potential role 
of this transporter on adrenal aldosterone output. 
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Figure 11: Transcriptional regulation of 
solute carrier family 26 member 2 
(slc26a2) in vivo in mice. SLC26A2 
expression is significantly downregulated 
in adrenals from wild-type animals on 
angiotensin II stimulation (A) and after a 
high potassium diet (B). Adapted from 
Spyroglou et al., 2014. 
To evaluate whether SLC26A2 function in adrenocortical cells would directly influence 
aldosterone secretion, we used a lentiviral based knockdown system in adrenocortical NCI-
H295R cells and achieved knockdown efficacy in the range of 20% of untreated cells 
(P<0.001; Figure 12A). In comparison with an unspecific, nontargeting shRNA construct 
which had no effect on aldosterone secretion specific knockdown of SLC26A2 caused a 
significant increase of aldosterone levels in the supernatant (P<0.001). Accordingly, 
aldosterone production after potassium and angiotensin II stimulation was further enhanced 
by SLC26A2 knockdown (Figure 12B). HSD3B2 and CYP11B2 expression were upregulated 
in knockdown cells under baseline conditions (HSD3B2: P<0.001; CYP11B2: P<0.001) and 
even more upon potassium and angiotensin II stimulation (Figure 12E and 13F). Similar, but 
overall less pronounced changes were observed for StAR and CYP11A1 expression (Figure 
12C and D).   
The role of adrenal SLC26A2 expression on aldosterone output was also investigated with a 
slc26a2 knock-in mouse model (p.A386V). The mutation induced here was initially identified 
in a patient with a mild phenotype of diastrophic dysplasia and provoked a partial loss of 
function of this sulfate transporter. Additionally, in this mouse model, the intronic cassette 
used caused splicing impairment of the mutant allele, resulting not only in structural protein 
changes but also in reduced expression levels of the mutant slc26a2 mRNA. The adrenal 
glands of mutant animals presented morphologically no changes in comparison to wild-type 
controls (Figure 13A–13D). However, as, expected, adrenal slc26a2 expression was 
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significantly lower in animals of both sexes (males: P<0.001; females: P<0.01; Figure 13E). 
Interestingly, aldosterone output was significantly increased only in female animals (P<0.01; 
Figure 13F), whereas male mice displayed only slight differences in their plasma aldosterone 
levels (P=0.27). Steroidogenic enzymes with a non-specific expression pattern (star, cyp11a1) 
or a zona fasciculata–specific distribution (hsd3b1) showed downregulation in the mutant 
mice (Figure 13G–13H). In contrast, adrenal enzymes with a specific role in aldosterone 
synthesis and preferential expression in the zona glomerulosa including hsd3b6 (Figure 13I) 
and cyp11b2 (Figure 13J) showed higher expression levels in mutant animals. Although some 
sex-specific changes were present, the steroidogenic enzymes’ expression profiles showed 
similar trends in slc26a2 mutant animals of both genders. 
In summary, these findings delineate a possible effect of SLC26A2 in the regulation of 
aldosterone secretion potentially involved in the pathogenesis of primary aldosteronism. 
 
 
 
 
Figure 12: Steroidogenesis is upregulated 
in adrenocortical cells on solute carrier 
family 26 member 2 (SLC26A2) 
knockdown. (A) SLC26A2 expression in 
untreated NCI-H295R cells, in NCI- 
H295R cells transfected with nontargeting 
shRNA (shCTRL), and in cells transfected 
with a specific SLC26A2 shRNA 
(shSLC26A2). (B) Aldosterone production 
and mRNA expression of (C) StAR, (D) 
CYP11A1, (E) HSD3B2, and (F) CYP11B2 
in control cells and specific knockdown 
cells at baseline conditions, on KCl and 
angiotensin II stimulation, respectively. 
*Significant differences between shCTRL 
and shSLC26A2 cells within an 
experimental condition, whereas # depict 
significant differences between baseline 
and stimulated cells: Adapted from 
Spyroglou et al., 2014. 
 
 
27 
 
 
Figure 13: Solute carrier family 26 member 2 (Slc26a2) mutant animals display higher 
aldosterone output in a sex-dependent manner. A–D: No gross alterations in adrenal 
morphology and zonation are evident in slc26a2 mutant animal in comparison with wild-type 
controls. E: As expected, adrenal slc26a2 mRNA expression is significantly lower in 
knockout animals. F: This difference is associated with higher serum aldosterone 
concentrations in female mice, lower expression of zone unspecific or zona fasciculata–
specific steroidogenic enzymes including Star (G) and cyp11a1 (H), and higher expression of 
glomerulosa-specific enzymes such as hsd3b6 (I) and cyp11b2 (J). Bars in A–D represent 50 
μm. Adapted from Spyroglou et al., 2014. 
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Discussion 
The studies presented herein had as initiating point the need to further elucidate mechanisms 
regulating the aldosterone secretion under physiological conditions and thereby to approach 
genetic alterations leading to aberrant aldosterone production in primary aldosteronism. 
Aldosterone values present strong gender dependency in C3HeB/FeJ mice, with male animals 
presenting significantly higher plasma aldosterone levels than females (Spyroglou et al., 
2012). Similarly, it could be documented that the corticosterone output of the murine adrenal 
gland is gender dependent (Spyroglou et al., 2015). In a small observational study 
investigating aldosterone levels in another strain (CD-1 mice) only small gender differences 
could be identified (Sun et al., 2010). Differences in the regulation of blood pressure between 
genders have already been described in human, with both pre- and postmenopausal women 
having lower blood pressure values than men (Burt et al., 1995) and women displaying lower 
aldosterone levels than men (Miller et al., 1999). Moreover, angiotensin II receptor levels 
were downregulated by estrogen replacement therapy in ovariectomized rats (Roesch et al., 
2000), all suggesting that the RAAS is estrogen dependent. 
Besides from gender differences, murine aldosterone synthesis varies between two inbred 
strains, with C57BL/6J animals displaying higher levels in comparison to C3HeB/FeJ mice 
(Spyroglou et al., 2012). Interestingly, in this study, plasma aldosterone levels were higher if 
the C57BL/6J strain was on the paternal side and were accompanied by respective expression 
pattern of steroidogenic enzymes in the adrenal glands. In population-based studies has been 
observed that a continuous spectrum of disease activity exists from normal renin–angiotensin–
aldosterone function in essential hypertension to low renin hypertension and primary 
aldosteronism with its normokalemic and hypokalemic variance (Hannemann et al., 2012). 
Furthermore, in a haplotype analysis of the human CYP11B2 gene, an association of a 
polymorphism with plasma aldosterone levels could be documented (Russo et al., 2002). 
Different inbred mouse strains could represent such examples of aldosterone variations. 
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Transcriptional activation and post-transcriptional modification of steroidogenic enzymes are 
the major regulatory mechanisms for acute and chronic modulation of adrenocortical steroid 
production and release (Christenson and Strauss 2001). Angiotensin II and extracellular K+ 
trigger the aldosterone response from glomerulosa cells and long-term stimulation results in 
increased synthesis of steroidogenic enzymes (Spät and Hunyadi 2004). Furthermore, short 
term K+ stimulation induces a significant increase in adrenal Cyp11b2 expression levels in 
vivo (Dierks et al., 2010). It was also shown, that the aldosterone response occurs already 
within minutes upon stimulation with angiotensin II, accompanied by fast changes in adrenal 
mRNA expression levels of steroidogenic enzymes, which were evident already 10 min after 
the stimulatory event (Spyroglou et al., 2009). In contrast to angiotensin-II-related changes of 
StAR and Cyp11a1 mRNA levels which were in a similar range than those of sham treated 
animals, probably due to endogenous ACTH stimulation (Stier et al., 2004), angiotensin II-
induced upregulation of Cyp11b2 was much more pronounced as compared with sham-
injection-induced changes. Regulation of Cyp11b2 expression within such a short period of 
time had not been reported previously. As elongation rate of mRNAs has been determined in 
the range of 18 nucleotides per second (Schafer et al., 1991), detectable upregulation of the 
investigated steroidogenic enzymes with a transcript size in the range of 855-1581 bp (for 
StAR, Cyp11a1 and Cyp11b2) is realistic.  
NGF1-B and Nurr1 have been identified as two transcription factors suggested to be involved 
in transcriptional regulation of Cyp11b2 expression (Bassett et al., 2004). Interestingly, we 
observed robust overexpression only of Nurr1 upon short-term angiotensin II stimulation, 
correlating also with the Cyp11b2 expression levels (Spyroglou et al., 2009). Thus, these 
results provide evidence that from both transcription factors which have been considered to be 
involved in aldosterone secretion, only Nurr1 is likely to have impact in short term 
aldosterone regulation. Accordingly, higher Nurr1 immunoreactivity was observed in Conn 
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adenomas in comparison with Cushing adenomas, whereas NGF1-B immunoreactivity 
showed no significant differences between the two groups (Lu et al., 2004). 
Utilization of an ENU mutagenesis screen for the parameter aldosterone led to the 
identification of significantly more female animals displaying the pathological phenotype of 
hyperaldosteronism (Spyroglou et al., 2011). Such a gender-specific phenomenon has already 
been observed in mice carrying a targeted deletion of TASK1 or both TASK1 and TASK3, 
where only female mice presented the phenotype of primary aldosteronism, and which was 
reversible upon testosterone treatment (Heitzmann et al., 2008, Davies et al., 2008). In other 
studies, the percentage of established mutant lines varied from 0.04-3% of all F1 animals 
screened (Mohan et al., 2008, Reijmers et al., 2006). In the present mutagenesis screen the 
percentage was 0.28% of all screened animals probably due to the strict selection criteria 
applied here (Spyroglou et al., 2011). Interestingly, in our screen the eight established lines 
displayed different patterns of inheritance of the pathological trait and since they derived from 
distinct ENU-treated founder males, various mutations are likely to contribute to the 
phenotype. In all established mouse lines the increased aldosterone levels were preserved in 
animals of at least three generations, indicating heritability of this phenotype (Spyroglou et 
al., 2011). Thereby, an ENU mutagenesis screen is an applicable approach for the 
investigation of genetic causes of hyperaldosteronism.  
Upon characterization of one of the established mouse lines seven candidate genes were 
recognized by exome sequencing (Perez-Rivas et al., 2017). However, none of those had a 
known function in aldosterone regulation and only Clstn3 had a pronounced expression in the 
murine adrenal gland. Although Clstn3 has not an known functional role in the RAAS, a 
hypothesis-free approach such as the ENU screen has the power of evoking unpredictable 
findings. Exome sequencing from patient samples (Beuschlein et al., 2013, 2014) and 
population-based genetic studies (Spyroglou et al., 2014) provide examples for the power of 
these strategies. From the seven genes identified in this mouse line, Atm, Tipin and Mapk6, all 
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located on chromosome 9 and apparently inherited in parallel, due to genetic linkage, seem 
not to be causative for the hyperaldosteronism phenotype. In contrast, SNVs on Sspo, Dguok, 
Hoxaas2 and Clstn3, all located on chromosome 6, were associated with a significant increase 
in aldosterone values of the respective mutant animals, suggesting a role of these genes in the 
phenotype of primary aldosteronism. Upon calculation of the aldosterone-to-renin ratio, only 
animals with the Sspo SNV showed higher ARRs in comparison to their wild-type littermates. 
Similarly, Sspo mutants also had significantly higher Cyp11b2 and Nurr1 expression levels, 
suggesting possibly a particular role of this gene in the described phenotype. However, Dguok 
mutants also presented relatively high Cyp11b2 and Nurr1 levels, Hoxaas2 mutants had 
significantly higher Nurr1 levels and Clstn3 mutants displayed the highest aldosterone values 
with the highest mutant-to-wild-type ratio. Furthermore, the increased adrenocortical 
CYP11B2 expression of mutant animals (carrying all four SNVs: Sspo, Dguok, Hoxaas2 and 
Clstn3) seems to be based on the presence of CYP11B2 expression in the middle and inner 
adrenocortical area (Perez-Rivas et al., 2017). Thereby, no safe conclusion on the effect of 
each of the four SNVs on the increased aldosterone production and altered adrenocortical 
zonation can be made. An interaction of more than one mutation, although not likely is still 
conceivable (Moreno et al., 2007, Tayo et al., 2016, Wei et al., 2015). 
The clinical hallmark of classical primary aldosteronism is hypokalemic hypertension with 
low plasma renin and elevated aldosterone. Thus, ARR is the standard screening method for 
this disease (Funder et al., 2008). Furthermore, a continuous gradient of higher possibility of 
blood pressure progression with increasing ARR levels has been documented (Newton-Cheh 
et al., 2007). Recently, several GWAS were applied for quantitative traits (Ehret et al., 2011, 
Köttgen et al., 2013, Scott et al., 2012, Kaplan et al., 2011). In a GWAS of a population-based 
sample, a highly significant correlation of ARR to a locus containing the SLC26A2 gene was 
identified (Spyroglou et al., 2014). SLC26A2 is present in many epithelial and connective 
tissues (Haila et al., 2001) and functions as SO42−/Cl− exchanger (Satoh et al., 1998) 
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providing SO42- for the sulphation of proteoglucans in cartilage (Forlino et al., 2005). 
SLC26A2 mutations cause diastrophic dysplasia, a phenotype of cartilage and bone 
malformations (Forlino et al., 2005). It was now demonstrated that SLC26A2 is highly 
expressed in the adrenal gland and is downregulated upon physiological aldosterone 
stimulation and autonomous aldosterone secretion (Spyroglou et al., 2014).  No somatic or 
germline mutations of SLC26A2 were documented so far in aldosterone producing adenomas 
(Beuschlein et al., 2013, Scholl et al., 2013, Azizan et al., 2013). Thus, possibly epigenetic 
mechanisms lead to expression changes of SLC26A2 with functional effect. Only female 
slc26a2 mutant animals displayed elevated plasma aldosterone values, suggesting also in this 
case a potentially sex-dependent phenotype, similarly to previously described gender 
dependent aldosterone differences (Heitzmann et al., 2008, El Wakil et al., 2012, Spyroglou et 
al., 2012). However, since no significant differences of SLC26A2 expression could be 
documented in APAs from both male and female patients, this hypothesis cannot be 
confirmed so far.  
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Summary 
 
Summarizing, the studies described herein have contributed to the understanding of the 
regulation of aldosterone secretion. Murine plasma aldosterone levels are gender dependent. 
Additionally, the genetic background of the animals plays a significant role modulating their 
aldosterone levels without clear interference of other parameters in the RAAS. Acute 
regulation of aldosterone synthesis is accompanied by fast transcriptional modulation of 
steroidogenic enzymes and transcription factors that are likely to be involved in aldosterone 
secretion. The different approaches used for the identification of genes involved in aberrant 
aldosterone regulation validate the described methods as applicable in the investigation of 
such an endocrine phenotype. A phenotype driven mutagenesis screen has been proven as a 
feasible method to detect and establish mutant mouse lines with a phenotype of chronic 
hyperaldosteronism. A detailed phenotypic and genetic characterization of one the established 
mouse lines revealed Sspo, Hoxaas2, Dguok and Clstn3 as new candidate genes involved in 
this trait. Based on a GWAS an effect of SLC26A2 in the regulation of aldosterone secretion 
and potential involvement in the pathogenesis of primary aldosteronism could be 
demonstrated in vitro and in vivo. The above described mouse lines can additionally serve in 
the future for pharmacological intervention studies, and thus in the development of new drug 
treatments for patients with hyperaldosteronism. 
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